Immunotherapy Collaborative of Networked Communities (IC-ONC)

Immunotherapy Collaborative of Networked Communities (IC-ONC) is an initiative designed to educate oncologists and the cancer team on advances in cancer immunotherapy. (IC-ONC) has been designed to build local communities that serve as the foundation of a global network in which multidisciplinary clinicians responsible for treating patients with cancer are connected via education.

LEARN MORE & JOIN THE COMMUNITY

 

A 3D Tour of Immuno-Oncology

View Activity
Order 3D Glasses

 

COURSE DIRECTORS AND FACULTY

Arjun V. Balar, MD (Course Director)
Assistant Professor of Medicine
Director—Genitourinary Medical
Oncology Program
NYU Perlmutter Cancer Center
NYU Langone Medical Center
New York, NY

Jeffery S. Weber, MD (Course Director)
Laura and Isaac Perlmutter Professor of Oncology
Department of Medicine
NYU Langone Medical Center
New York, NY

Jason Luke, MD
Assistant Professor of Medicine
The University of Chicago Medicine
Chicago, IL

PROGRAM OVERVIEW

This case-based enduring activity will cover the diagnosis, treatment and management of patients with cancer who are treated or eligible for treatment with immunotherapy.

TARGET AUDIENCE

This activity is designed to meet the educational needs of oncologists, oncology pharmacists, oncology nurses and other healthcare professionals involved in the management of patients with cancer who are treated or eligible for treatment with immunotherapy.

LEARNING OBJECTIVES

Upon completion of the program, attendees should be able to:

  • Describe the complex interactions between cancer cells, the tumor microenvironment and the immune system, and the mechanism of action of immune checkpoints inhibitors
  • Review clinical evidence to select which patients most benefit from new cancer immunotherapies and how to sequence them or combine them with other treatments
  • Critically evaluate clinical data of CTLA4 and PD-1/PD- L1 inhibitors, with a focus on the modality of response and the rationale for combination therapy
  • Recognize and manage immune-related adverse events (irAEs) associated with novel cancer immunotherapies

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this enduring activity for a maximum of 3.0 AMA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with cancer who are treated or eligible for treatment with immunotherapy.
Credits: 3.00 ANCC Contact Hour(s)

ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 3.0 contact hour(s) of continuing nursing education of RNs and APNs.

ILNA CODING ONCC RECERTIFICATION

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. ONCC review is only for designating content to be used for recertification points and is not for CNE accreditation. CNE programs must be formally approved for contact hours by an acceptable accreditor/ approver of nursing CE to be used for recertification by ONCC. If the CNE provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification may be used in relation to the program.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF FINANCIAL RELATIONSHIPS

Dr Balar has received consultant fees from Merck, Genentech, AstraZeneca, and Pfizer; fees for Non-CME/CE Services received directly from a commercial interest or its agent from Merck, Genentech, and AstraZeneca.
Dr Weber has intellectual property or is a patent holder with Biodesix, has received consultant fees from BMS, Merck, Incyte, Genentech, GSK, AstraZeneca, EMS Serono, and Novartis; has ownership interests in Celldux, Alton, and Cytomx.
Dr Luke has received consultant fees from 7 Hills, Actym, Amgen, Array, AstraZeneca, Bristol- Myers Squibb, Castle, CheckMate, EMD Serono, Gilead, Janssen, Merck, NewLink, Nimbus, Novartis, Palleon, RefleXion, Syndax, and Tempest; and received clinical trial support from Abbvie, Boston BioMedical, Bristol-Myers Squibb, Celldex, Corvus, Delcath, Five Prime, Genentech, Immunocore, Incyte, Intensity, MedImmune, Macrogenics, Novartis, Pharmacyclics, Merck, and Tesaro.

The independent reviewers, staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests:

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

Staff, Planners and Managers

Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Brooke Hefele, Outcomes Coordinator for Med Learning Group has nothing to disclose.
Chelsey Goins, PhD, Medical Director, Scientific and Medical Services for Med Learning Group has nothing to disclose.
Lisa Dorin, Senior Program Manager for Med Learning Group has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME/CNE credit for this enduring activity. To receive CME/CNE credit participants must:
1. Read the CME/CNE information and faculty disclosures.
2. Participate in the live activity.
3. Submit the evaluation form to Med Learning Group.

You will receive your certification via email within 30 days.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision‐making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact: Med Learning Group at info@medlearninggroup.com.

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: http://www.medlearninggroup.com/privacy-policy/

RELEASE DATE: April 25, 2018

EXPIRATION DATE: April 25, 2019

Order 3D Glasses

View Activity

Participation Statement
This educational activity provides training necessary for licensed attendees to maintain state licensing requirements. The tuition for this educational activity is subsidized in part by unrestricted educational grants, including for those attendees who have successfully completed the state licensing requirements for their respective fields. This subsidy is reflected in the registration fees for this activity.

Copyright © 2018 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.